X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (705) 705
Publication (52) 52
Newspaper Article (44) 44
Newsletter (30) 30
Book Chapter (12) 12
Book Review (11) 11
Magazine Article (7) 7
Transcript (7) 7
Dissertation (3) 3
Conference Proceeding (2) 2
Data Set (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
axitinib (769) 769
index medicus (421) 421
humans (359) 359
oncology (343) 343
sorafenib (289) 289
sunitinib (243) 243
cancer (215) 215
male (192) 192
carcinoma, renal cell - drug therapy (183) 183
carcinoma, renal cell (182) 182
renal cell carcinoma (180) 180
female (178) 178
kidney neoplasms - drug therapy (169) 169
middle aged (165) 165
metastasis (161) 161
vascular endothelial growth factor (142) 142
aged (137) 137
care and treatment (134) 134
everolimus (112) 112
drug therapy (110) 110
pazopanib (110) 110
adult (106) 106
antineoplastic agents - therapeutic use (106) 106
kidney cancer (106) 106
treatment outcome (106) 106
pharmacology & pharmacy (105) 105
kidney neoplasms - pathology (103) 103
survival (100) 100
efficacy (98) 98
interferon-alpha (98) 98
research (95) 95
imidazoles - therapeutic use (94) 94
indazoles - therapeutic use (93) 93
protein kinase inhibitors - therapeutic use (92) 92
bevacizumab (90) 90
analysis (86) 86
disease-free survival (86) 86
targeted therapy (84) 84
carcinoma, renal cell - pathology (83) 83
medicine & public health (79) 79
angiogenesis (75) 75
trial (74) 74
clinical trials (71) 71
tyrosine kinase inhibitor (70) 70
therapy (67) 67
phase-ii (66) 66
pharmaceutical industry (64) 64
double-blind (63) 63
safety (63) 63
animals (62) 62
metastatic renal cell carcinoma (61) 61
renal-cell carcinoma (61) 61
chemotherapy (60) 60
tumors (60) 60
antineoplastic agents - adverse effects (59) 59
dosage and administration (58) 58
immunotherapy (58) 58
tyrosine (58) 58
aged, 80 and over (57) 57
endothelial growth-factor (57) 57
imidazoles - adverse effects (57) 57
indazoles - adverse effects (57) 57
urology & nephrology (57) 57
imidazoles - administration & dosage (56) 56
indazoles - administration & dosage (56) 56
health aspects (55) 55
inhibitor (53) 53
patients (53) 53
protein kinase inhibitors - adverse effects (53) 53
cancer therapies (52) 52
receptors, vascular endothelial growth factor - antagonists & inhibitors (51) 51
imidazoles - pharmacology (50) 50
indazoles - pharmacology (50) 50
tyrosine kinase inhibitors (50) 50
niacinamide - analogs & derivatives (49) 49
open-label (49) 49
hypertension (48) 48
retrospective studies (46) 46
carcinoma (45) 45
carcinoma, renal cell - secondary (45) 45
prognosis (45) 45
angiogenesis inhibitors - therapeutic use (44) 44
antimitotic agents (44) 44
antineoplastic agents (44) 44
protein kinase inhibitors - pharmacology (44) 44
patient outcomes (43) 43
solid tumors (43) 43
ag-013736 (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
clear cell-type renal cell carcinoma (41) 41
protein kinase inhibitors - administration & dosage (41) 41
development and progression (40) 40
vegf (40) 40
cabozantinib (39) 39
pharmacology/toxicology (39) 39
medical prognosis (38) 38
medical research (38) 38
pharmacokinetics (38) 38
metastases (37) 37
hematology, oncology and palliative medicine (36) 36
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (754) 754
German (18) 18
Russian (12) 12
French (9) 9
Japanese (8) 8
Czech (3) 3
Polish (3) 3
Spanish (2) 2
Chinese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 03/2019, Volume 380, Issue 12, pp. 1116 - 1127
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2019, Volume 380, Issue 12, pp. 1103 - 1115
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2018, Volume 36, Issue 36, pp. 3639 - 3644
The treatment of metastatic clear cell renal cancer is changing rapidly, with the focus switching from vascular endothelial growth factor-targeted therapies to... 
GROWTH-FACTOR | AXITINIB | ONCOLOGY | CARCINOMA
Journal Article
The Oncologist, ISSN 1083-7159, 02/2019, Volume 24, Issue 2, pp. 143 - 145
This commentary reviews the novel mechanism of action of TRC105 in the context of treatments currently available for metastatic renal cell carcinoma,... 
AXITINIB | ONCOLOGY | COMBINATION | CANCER
Journal Article
The Lancet Oncology, ISSN 1470-2045, 03/2018, Volume 19, Issue 3, pp. 405 - 415
Journal Article
by Liu, XS and Wang, BL and Chen, C and Qi, ZP and Zou, FM and Wang, JJ and Hu, C and Wang, AL and Ge, J and Liu, QW and Yu, KL and Hu, ZQ and Jiang, ZR and Wang, W and Wang, L and Wang, WC and Ren, T and Bai, MF and Liu, QS and Liu, J
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 05/2019, Volume 62, Issue 10, pp. 5006 - 5024
Gain-of-function mutations of c-KIT kinase play crucial pathological roles for the gastrointestinal stromal tumors (GISTs). Despite the success of imatinib as... 
CELLS | CHEMISTRY, MEDICINAL | AXITINIB | EFFICACY | SAFETY | IMATINIB | RESISTANCE | SUNITINIB | MECHANISMS
Journal Article
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. 725 - 727
Combination therapies involving antiangiogenic agents plus immune checkpoint inhibitors have recently demonstrated clinical efficacy in advanced renal cell... 
EVEROLIMUS | AXITINIB | ONCOLOGY | BEVACIZUMAB | SUNITINIB | COMBINATION | NIVOLUMAB | CANCER | Commentaries
Journal Article
PLoS ONE, ISSN 1932-6203, 04/2019, Volume 14, Issue 4, p. e0213942
Journal Article
Clinical Genitourinary Cancer, ISSN 1558-7673, 12/2019
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was... 
renal cell carcinoma | hyperkalemia | adverse event | axitinib
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 03/2018, Volume 24, Issue 5, pp. 1030 - 1037
Purpose: We hypothesized that axitinib is active with an improved safety profile in nasopharyngeal carcinoma (NPC). Experimental Design: We evaluated axitinib... 
TRIAL | CANCER-PATIENTS | THERAPY | SOLID TUMORS | ONCOLOGY | RECURRENT | RADIOTHERAPY | PATIENTS PTS | COMBINATION | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | Axitinib - administration & dosage | Pain - epidemiology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Axitinib - pharmacokinetics | Diarrhea - epidemiology | Male | Response Evaluation Criteria in Solid Tumors | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Pain - chemically induced | Weight Loss - drug effects | Diarrhea - chemically induced | Nasopharyngeal Neoplasms - pathology | Neoplasm Recurrence, Local - pathology | Young Adult | Antineoplastic Agents - adverse effects | Nasopharyngeal Neoplasms - blood | Hypertension - chemically induced | Inhibitory Concentration 50 | Adult | Female | Antineoplastic Agents - pharmacokinetics | Hypertension - epidemiology | Nasopharyngeal Neoplasms - drug therapy | Axitinib - adverse effects | Nasopharyngeal Carcinoma - blood | Neoplasm Recurrence, Local - blood | Thyrotropin - blood | Drug Administration Schedule | Hemorrhage - epidemiology | Disease Progression | Xenograft Model Antitumor Assays | Animals | Fatigue - epidemiology | Nasopharyngeal Carcinoma - pathology | Cell Line, Tumor | Nasopharyngeal Carcinoma - drug therapy | Aged | Mice | Hemorrhage - chemically induced | Hypertension | Slopes | Toxicity | Diarrhea | Fatigue | Pharmacology | Hypothyroidism | Disease control | Patients | Hemorrhage | Metastases | Nasopharyngeal carcinoma | Thyroid-stimulating hormone | Chemotherapy | Pain | Experimental design | Platinum | Correlation analysis | Safety engineering | Blood pressure | Safety | Pharmacokinetics | Thyroid
Journal Article
Anti-Cancer Drugs, ISSN 0959-4973, 08/2018, Volume 29, Issue 7, pp. 705 - 709
Journal Article
Acta Pharmacologica Sinica, ISSN 1671-4083, 02/2019, Volume 40, Issue 2, pp. 243 - 256
Journal Article
European Heart Journal, ISSN 0195-668X, 09/2016, Volume 37, Issue 36, pp. 2740 - 2742
Journal Article
ONCOLOGIST, ISSN 1083-7159, 02/2015, Volume 20, Issue 2, pp. 196 - 201
Axitinib is a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR-1), VEGFR-2, and VEGFR-3. Based on the positive opinion from... 
ONCOLOGY | Renal cell carcinoma | EMA | Axitinib | Inlyta | European Medicines Agency
Journal Article
The Journal of urology, ISSN 0022-5347, 01/2020, Volume 203, Issue 1, pp. 28 - 29
Journal Article
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 04/2018, Volume 22, Issue 4, pp. 2153 - 2161
Aberrant receptor kinase signalling and tumour neovascularization are hallmarks of medulloblastoma development and are both considered valuable therapeutic... 
multi-kinase inhibitor | MEDICINE, RESEARCH & EXPERIMENTAL | targeted therapy | medulloblastoma | SAFETY | PLUS AXITINIB | PI3K inhibitor | PHASE-II | SORAFENIB | COMBINATION | GDC-0941 | RENAL-CELL CARCINOMA | CELL BIOLOGY | TYROSINE KINASE INHIBITORS | THERAPY | GROWTH ARREST | VIVO EFFICACY | Axitinib
Journal Article